

Anti-Inflammatory Reliever (AIR) Therapy

BUDESONIDE + FORMOTEROL
Symbicort® DuoResp Spiromax®



100/6 200/6200/6
Turbuhaler®

Dry powder inhaler

Short-Acting Beta2 Agonists (SABA)

SALBUTAMOL **TERBUTALINE**
SalAir® Ventolin® Bricanyl®



100 mcg
Aerosol inhaler

250 mcg
Turbuhaler®

Short-Acting Muscarinic Antagonists (SAMA)

IPRATROPIUM
Atrovent®



20 mcg
Aerosol inhaler

Combination SABA + SAMA

SALBUTAMOL + IPRATROPIUM
Duolin HFA®



100 mcg/20 mcg
Aerosol inhaler

Relievers

Inhaled Corticosteroids (ICS)

FLUTICASONE propionate
Flixotide®



50 mcg 125 mcg 250 mcg
Aerosol inhaler

50 mcg 100 mcg 250 mcg
Accuhaler®

BUDESONIDE
Pulmicort®



100 mcg 200 mcg 400 mcg
Turbuhaler®

BECLOMETHASONE dipropionate
Beclazone® Qvar® (ultrafine particle)



50 mcg 100 mcg 250 mcg 50 mcg 100 mcg
Aerosol inhalers

Note: Beclazone® and Qvar® are not dose equivalent and are not interchangeable.

Preventers

Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA)

BUDESONIDE + FORMOTEROL
Symbicort® DuoResp Spiromax® Vannair®



100/6 200/6 400/12*
Turbuhaler®

200/6 400/12*
Dry powder inhaler

100/6 200/6
Aerosol inhaler

*Symbicort 400/12 and DuoResp Spiromax 400/12 only funded if no more than 2 doses per day
Note: Symbicort 100/6, 200/6 and DuoResp Spiromax 200/6 are currently approved for Anti-Inflammatory Reliever (AIR) therapy. Vannair 100/6 and 200/6 is approved for maintenance use, but its use in AIR therapy is an unapproved indication.

Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA)

FLUTICASONE propionate + SALMETEROL
Seretide®



50/25 125/25 250/25
Aerosol inhaler

100/50* 250/50*
Accuhaler®

*100/50 and 250/50 accuhaler only funded if no more than 2 doses per day

FLUTICASONE furoate + VILANTEROL
Breo Ellipta®



100/25 200/25
Dry powder inhaler

Controller + Preventer

Long-Acting Beta2 Agonists (LABA)

SALMETEROL
Serevent®



25 mcg 50 mcg
Aerosol inhaler Accuhaler®

FORMOTEROL (eformoterol)
Oxis®



6 mcg
Turbuhaler®

INDACATEROL
Onbrez Breezhaler®



150 mcg 300 mcg
Breezhaler®

Long-Acting Muscarinic Antagonists (LAMA)

TIOTROPIUM
Spiriva®



18 mcg
Handihaler®

Spiriva Respimat®



2.5 mcg
Fine mist inhaler

UMECLIDINIUM
Incruse Ellipta®



62.5 mcg
Dry powder inhaler

GLYCOPYRRONIUM
Seebri Breezhaler®



50 mcg
Breezhaler®

Funded by endorsement: LAMA inhaler is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly (i.e. COPD documented as indication on prescription).
Not subsidised if patient is also receiving treatment with another subsidised LAMA.

Combination Long-Acting Muscarinic Antagonists (LAMA) + Long-Acting Beta2 Agonists (LABA)

TIOTROPIUM + OLODATEROL
Spioolto Respimat®



2.5 mcg/2.5 mcg
Fine mist inhaler

UMECLIDINIUM + VILANTEROL
Anoro Ellipta®



62.5 mcg/25 mcg
Dry powder inhaler

GLYCOPYRRONIUM + INDACATEROL
Ultibro Breezhaler®



50 mcg/110 mcg
Breezhaler®

Funded via Special Authority: LAMA + LABA inhaler is subsidised only for patients who have been stabilised on a LAMA and the prescriber considers that the patient would receive additional benefit from switching to a combination product. Not subsidised if patient is also receiving treatment with a combination ICS and LABA.

Combination Inhaled Corticosteroids (ICS) + Long-Acting Muscarinic Antagonist (LAMA) + Long-Acting Beta2 Agonist (LABA)

FLUTICASONE furoate + UMECLIDINIUM + VILANTEROL
Trelegy Ellipta®



100 mcg/62.5 mcg/25 mcg
Dry powder inhaler

BUDESONIDE + GLYCOPYRRONIUM + FORMOTEROL
Breztri Aerosphere®



160 mcg/7.2 mcg/5 mcg
Aerosol inhaler

Funded via Special Authority: ICS + LAMA + LABA 'triple therapy' inhaler is subsidised only for patients with a diagnosis of COPD confirmed by spirometry, or spirometry has been attempted and technically acceptable results are not possible and the patient is currently on an ICS/LABA or a LAMA/LABA, and meets the following clinical criteria:
• Patient has a COPD Assessment Test (CAT) score greater than 10, or
• Patient has had 2 or more exacerbations in the previous 12 months, or
• Patient has had one exacerbation requiring hospitalisation in the previous 12 months, or
• Patient has had an eosinophil count greater than or equal to 0.3×10^9 cells/L in the previous 12 months
or the patient is currently receiving multiple inhaler triple therapy (ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to starting multiple inhaler triple therapy.

Long-acting Symptom Controllers (for COPD)

Spacers are available free to those who need them on a Practitioners Supply Order (PSO). Contact Health New Zealand | Te Whatu Ora for an order form on 0800 855 066. Everyone should have an action plan. Find a range of management plans at cardiacandrespiratory.org.nz

✓ Funded ✗ Not funded ✗ Partially funded

✓ Funded by endorsement ✗ Funded by Special Authority

✓ Low carbon footprint! ✗ High carbon footprint!

Funding information updated as of 1 June 2025.

Visit www.pharmac.govt.nz

cardiacandrespiratory.org.nz